BioNTech
NEWS
News on COVID-19 vaccine developments and disease studies continue to deliver highs and lows. Here are some of the more recent happenings.
The beginning of booster vaccines for adults was in news for a long time. Well, CDS authorized it now, and here’s the reason behind the authorization.
The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.
BioNTech is on the Fast Track. This morning, the company announced it received Fast Track Designation from the U.S. Food and Drug Administration for its cancer immunotherapy candidate.
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.
While COVID-19 appears to be surging again in the U.S. and Europe, the government is spending billions to acquire antibody and antiviral therapies and edging toward vaccination boosters.
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
JOBS
IN THE PRESS